VP-16, IFOSFAMIDE AND CISPLATIN (VIP) FOR EXTENSIVE SMALL-CELL LUNG-CANCER

Thirty-seven extensive disease SCLC patients were treated with ifosfamide 1.0 g/m(2) (maximum 1.75 g), VP-16 (etoposide) 75 mg/m(2) and cisplatin 20 mg/m(2) (VIP) daily for 5 days in hospital. Mesna was given as a continuous infusion until 12 h after the last ifosfamide dose. Treatment was reduced to 4 days after the first 8 patients experienced serious myelotoxicity. 30 patients were evaluable for response. 8 (27%) achieved a complete response and 60% had a partial response. The median duration of response was 23 weeks. The median survival of all 37 patients was 41 weeks, and 47 weeks for the 30 evaluable patients. Fifty per cent and 26% of the evaluable treatment courses were associated with grade 4 and 3 granulocytopenia, respectively. There were eight febrile events including four treatment-related deaths from sepsis on the 5-day regimen. Although the response to VIP was generally rapid, the proportion achieving complete response (27% of evaluable patients) and the median survival is similar to standard chemotherapy regimens which are less toxic and less complex to administer.